EP4397309A3 - Composés cétoniques bicycliques et leurs procédés d'utilisation - Google Patents

Composés cétoniques bicycliques et leurs procédés d'utilisation Download PDF

Info

Publication number
EP4397309A3
EP4397309A3 EP24152498.2A EP24152498A EP4397309A3 EP 4397309 A3 EP4397309 A3 EP 4397309A3 EP 24152498 A EP24152498 A EP 24152498A EP 4397309 A3 EP4397309 A3 EP 4397309A3
Authority
EP
European Patent Office
Prior art keywords
methods
ketone compounds
bicyclic ketone
compounds
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24152498.2A
Other languages
German (de)
English (en)
Other versions
EP4397309A2 (fr
Inventor
Snahel PATEL
Gregory Hamilton
Guiling Zhao
Huifen Chen
Blake DANIELS
Craig STIVALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP4397309A2 publication Critical patent/EP4397309A2/fr
Publication of EP4397309A3 publication Critical patent/EP4397309A3/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EP24152498.2A 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation Pending EP4397309A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
EP18740815.8A EP3652178B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation
PCT/EP2018/068998 WO2019012063A1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP18740815.8A Division EP3652178B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP4397309A2 EP4397309A2 (fr) 2024-07-10
EP4397309A3 true EP4397309A3 (fr) 2024-09-04

Family

ID=62916677

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18740815.8A Active EP3652178B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation
EP24152498.2A Pending EP4397309A3 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18740815.8A Active EP3652178B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Country Status (30)

Country Link
US (3) US11098058B2 (fr)
EP (2) EP3652178B1 (fr)
JP (2) JP7258843B2 (fr)
KR (2) KR20240065201A (fr)
CN (1) CN110914271A (fr)
AR (1) AR112274A1 (fr)
AU (3) AU2018300043B2 (fr)
BR (1) BR112020000771A2 (fr)
CA (2) CA3185865A1 (fr)
CL (1) CL2020000101A1 (fr)
CO (1) CO2020000134A2 (fr)
CR (1) CR20200002A (fr)
DK (1) DK3652178T3 (fr)
ES (1) ES2973661T3 (fr)
FI (1) FI3652178T3 (fr)
HR (1) HRP20240354T1 (fr)
HU (1) HUE065793T2 (fr)
IL (2) IL271981B (fr)
LT (1) LT3652178T (fr)
MA (1) MA49560B1 (fr)
NZ (1) NZ760749A (fr)
PH (1) PH12020500105A1 (fr)
PL (1) PL3652178T3 (fr)
PT (1) PT3652178T (fr)
RS (1) RS65308B1 (fr)
SG (1) SG11202000333UA (fr)
SI (1) SI3652178T1 (fr)
TW (1) TWI805595B (fr)
UA (1) UA125448C2 (fr)
WO (1) WO2019012063A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831478A (zh) * 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
EP3652178B1 (fr) 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Composés cétoniques bicycliques et leurs procédés d'utilisation
RU2020115915A (ru) 2017-10-31 2021-12-01 Ф. Хоффманн-Ля Рош Аг Бициклические сульфоны и сульфоксиды и способы их применения
JP2022516651A (ja) * 2019-01-11 2022-03-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
WO2021198981A1 (fr) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Composés antiviraux et leurs utilisations
EP4144720A4 (fr) * 2020-04-27 2024-06-19 Autotac Inc. Composé en tant que ligand du domaine ubr-box
BR112023020229A2 (pt) 2021-04-02 2023-11-14 Hoffmann La Roche Processos para a preparação de um composto bicíclico de cetona quiral, composto de n-amino lactama quiral, composto de sal imidato e composto hidroxicetoéster, composto, ou um sal farmaceuticamente aceitável do mesmo e invenção
WO2023039795A1 (fr) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Inhibiteur de la kinase rip1 et son utilisation
WO2023225041A1 (fr) * 2022-05-19 2023-11-23 Merck Sharp & Dohme Llc Inhibiteurs de ripk1 et procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014125444A1 (fr) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques à utiliser en tant qu'inhibiteurs de kinase

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0652775B1 (fr) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Ciblage de liposomes sur la barriere hemato-encephalique
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
JP2002512628A (ja) 1997-06-13 2002-04-23 スージェン・インコーポレーテッド タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
WO2005025511A2 (fr) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
CA2605899C (fr) 2005-04-26 2011-02-08 Pfizer Limited Derives de triazole utilises comme antagonistes de la vasopressine
EP2083009A1 (fr) 2008-01-22 2009-07-29 Grünenthal GmbH Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
UY32776A (es) 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
CA2852964A1 (fr) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Composes piperazines bicycliques
JP6267193B2 (ja) 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
RU2015131314A (ru) 2013-01-18 2017-02-27 Ф. Хоффманн-Ля Рош Аг 3-замещенные пиразолы и их применение в качестве ингибиторов dlk
PE20161063A1 (es) 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
WO2015006280A1 (fr) 2013-07-10 2015-01-15 Vertex Pharmaceuticals Incorporated Amides de pipéridine fusionnés utiles en tant que modulateurs de canaux ioniques
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
WO2016027253A1 (fr) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments
WO2016128908A1 (fr) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales correspondantes
JP6701225B2 (ja) 2015-03-09 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式ｄｌｋ阻害剤及びその使用
CN112979660A (zh) 2015-07-02 2021-06-18 豪夫迈·罗氏有限公司 二环内酰胺和其应用方法
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
WO2017109724A1 (fr) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3566471B1 (fr) 2017-01-05 2022-09-28 Microsoft Technology Licensing, LLC Simulation audio pour jeux vidéo avec chemins de propagation indirects
EP3652178B1 (fr) 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Composés cétoniques bicycliques et leurs procédés d'utilisation
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
RU2020115915A (ru) 2017-10-31 2021-12-01 Ф. Хоффманн-Ля Рош Аг Бициклические сульфоны и сульфоксиды и способы их применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014125444A1 (fr) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques à utiliser en tant qu'inhibiteurs de kinase

Also Published As

Publication number Publication date
ES2973661T3 (es) 2024-06-21
AU2023203292A1 (en) 2023-06-22
HRP20240354T1 (hr) 2024-06-07
PL3652178T3 (pl) 2024-05-06
AU2021204369A1 (en) 2021-07-29
IL271981A (en) 2020-02-27
AU2018300043B2 (en) 2021-04-01
FI3652178T3 (fi) 2024-03-19
EP3652178B1 (fr) 2024-01-24
HUE065793T2 (hu) 2024-06-28
JP2020526549A (ja) 2020-08-31
NZ760749A (en) 2024-08-30
KR20240065201A (ko) 2024-05-14
RS65308B1 (sr) 2024-04-30
CA3067944C (fr) 2023-03-14
PH12020500105A1 (en) 2020-11-09
LT3652178T (lt) 2024-04-10
MA49560B1 (fr) 2024-05-31
RU2020106375A3 (fr) 2022-03-25
JP7258843B2 (ja) 2023-04-17
CN110914271A (zh) 2020-03-24
US20240300974A1 (en) 2024-09-12
CO2020000134A2 (es) 2020-01-17
CA3185865A1 (fr) 2019-01-17
WO2019012063A1 (fr) 2019-01-17
SI3652178T1 (sl) 2024-05-31
RU2020106375A (ru) 2021-08-16
PT3652178T (pt) 2024-03-18
US11098058B2 (en) 2021-08-24
US20190100530A1 (en) 2019-04-04
KR102664604B1 (ko) 2024-05-14
TW201920149A (zh) 2019-06-01
CL2020000101A1 (es) 2020-07-17
DK3652178T3 (da) 2024-03-25
EP4397309A2 (fr) 2024-07-10
US20210139504A1 (en) 2021-05-13
IL271981B (en) 2022-09-01
TWI805595B (zh) 2023-06-21
AU2018300043A1 (en) 2020-01-16
US11834461B2 (en) 2023-12-05
CA3067944A1 (fr) 2019-01-17
CR20200002A (es) 2020-02-10
IL294961A (en) 2022-09-01
EP3652178A1 (fr) 2020-05-20
AR112274A1 (es) 2019-10-09
MA49560A (fr) 2020-05-20
JP2023085449A (ja) 2023-06-20
UA125448C2 (uk) 2022-03-09
KR20200030558A (ko) 2020-03-20
BR112020000771A2 (pt) 2020-07-14
SG11202000333UA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
EP4397309A3 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
PH12021500014A1 (en) Fused ring compounds
WO2020097537A3 (fr) Composés cycliques fondus
WO2018136202A3 (fr) Composés et procédés pour la modulation de cdk8, et indications associées
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
EP4248968A3 (fr) Antagonistes de tlr7/8 et leurs utilisations
MX2019015744A (es) Composiciones farmaceuticas.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
CR20220251A (es) Nuevos derivados de metilquinazolinona
AU2018253590A1 (en) Imidazopyridazine compounds
ZA202309446B (en) Rapamycin analogs and uses thereof
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
WO2018039077A8 (fr) Composés thérapeutiques
EP3935037A4 (fr) Utilisation de composés de 8,9-dihydrocannabidiol
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
WO2018211324A8 (fr) Promédicaments pour traiter une maladie
AU2016250265A8 (en) (S)-2'-vinyl-abscisic acid derivatives
SA521421375B1 (ar) عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها
WO2020086650A3 (fr) Nouveaux composés

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3652178

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031536500

Ipc: C07D0487040000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5365 20060101ALI20240730BHEP

Ipc: A61K 31/437 20060101ALI20240730BHEP

Ipc: A61K 31/41 20060101ALI20240730BHEP

Ipc: A61P 25/28 20060101ALI20240730BHEP

Ipc: A61P 25/16 20060101ALI20240730BHEP

Ipc: C07D 498/04 20060101ALI20240730BHEP

Ipc: C07D 487/04 20060101AFI20240730BHEP